婴幼儿高级别胶质瘤在组织学、分子和临床上具有多样性:SJYC07试验及机构经验结果
该研究将SJYC07试验中组织学诊断高级别胶质瘤(HGG)的患儿与2007年11月至2020年12月在圣犹大儿童研究医院治疗的非方案HGG患儿合并,进行DNA甲基化谱和基因组测序并整合病理得出整合诊断。56例患儿(0.0-4.4岁)被分为婴儿型半球胶质瘤(IHG)、HGG、低级别胶质瘤(LGG)和其他中枢神经系统肿瘤四类,IHG最常见(n=22)且年龄最小(中位年龄0.4岁),常携带受体酪氨酸激酶基因融合;IHG的5年无事件生存(EFS)和总生存(OS)分别为53.13%(95%CI: 35.52-79.47)和90.91%(95%CI: 79.66-100.00),HGG分别为0.0%和16.67%(95%CI: 2.78-99.74%)(p=0.0043,p=0.00013)。
要点
- 婴幼儿HGG异质性大,整合组织病理和分子特征可将其分为IHG、HGG、LGG和其他CNS肿瘤四类。
- IHG最常见(n=22),中位年龄0.4岁,常携带ALK、ROS1、NTRK1/2/3、MET等受体酪氨酸激酶基因融合。
- IHG的5年EFS和OS分别为53.13%和90.91%,HGG分别为0.0%和16.67%,IHG与LGG的EFS和OS无差异(p=0.95,p=0.43)。
核心结论
- 幼儿HGG具有异质性,最好通过整合组织病理学和分子特征来定义;IHG患者结局相对较好,但仍承受显著缺陷,是治疗降阶梯和分子靶向治疗试验的良好候选者。
研究设计与样本
- SJYC07试验中组织学诊断HGG的患儿队列,加上2007年11月至2020年12月在圣犹大儿童研究医院治疗的非方案HGG患儿。
- 进行DNA甲基化谱分析以及全基因组、全外显子组和RNA测序,并将这些数据与组织病理学整合以得出整合诊断。
- 分析临床特征和术前影像。
主要发现
- 共识别56例儿童(0.0-4.4岁),整合分析将队列分为四类:婴儿型半球胶质瘤(IHG)、HGG、低级别胶质瘤(LGG)和其他中枢神经系统(CNS)肿瘤。
- IHG最常见(n=22),发生于最年轻的患者(中位年龄=0.4岁),常携带受体酪氨酸激酶基因融合(7例ALK,2例ROS1,3例NTRK1/2/3,4例MET)。
- IHG的5年无事件生存(EFS)和总生存(OS)分别为53.13%(95%CI: 35.52-79.47)和90.91%(95%CI: 79.66-100.00),HGG分别为0.0%和16.67%(95%CI: 2.78-99.74%)(p=0.0043,p=0.00013)。
- IHG与LGG之间的EFS和OS无差异(p=0.95,p=0.43)。
- 影像学回顾显示IHG与边界清楚(p=0.0047)、半球位置(p=0.0010)和瘤内出血(p=0.0149)相关。
临床怎么用
- 作者认为,IHG患者结局相对较好但仍承受显著缺陷,是治疗降阶梯和分子靶向治疗试验的良好候选者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade gliomas (HGG) in young children pose a challenge due to favorable but unpredictable outcomes. While retrospective studies broadened our understanding of tumor biology, prospective data is lacking. METHODS: A cohort of children with histologically diagnosed HGG from the SJYC07 trial was augmented with nonprotocol patients with HGG treated at St. Jude Children's Research Hospital from November 2007 to December 2020. DNA methylome profiling and whole genome, whole exome, and RNA sequencing were performed. These data were integrated with histopathology to yield an integrated diagnosis. Clinical characteristics and preoperative imaging were analyzed. RESULTS: Fifty-six children (0.0-4.4 years) were identified. Integrated analysis split the cohort into four categories: infant-type hemispheric glioma (IHG), HGG, low-grade glioma (LGG), and other-central nervous system (CNS) tumors. IHG was the most prevalent (n = 22), occurred in the youngest patients (median age = 0.4 years), and commonly harbored receptor tyrosine kinase gene fusions (7 ALK, 2 ROS1, 3 NTRK1/2/3, 4 MET). The 5-year event-free (EFS) and overall survival (OS) for IHG was 53.13% (95%CI: 35.52-79.47) and 90.91% (95%CI: 79.66-100.00) vs. 0.0% and 16.67% (95%CI: 2.78-99.74%) for HGG (p = 0.0043, p = 0.00013). EFS and OS were not different between IHG and LGG (p = 0.95, p = 0.43). Imaging review showed IHGs are associated with circumscribed margins (p = 0.0047), hemispheric location (p = 0.0010), and intratumoral hemorrhage (p = 0.0149). CONCLUSIONS: HGG in young children is heterogeneous and best defined by integrating histopathological and molecular features. Patients with IHG have relatively good outcomes, yet they endure significant deficits, making them good candidates for therapy de-escalation and trials of molecular targeted therapy.
引用
- Chiang J, Bagchi A, Li X, et al. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience. Neuro Oncol. 2024. PMID: 37503880. doi:10.1093/neuonc/noad130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。